Skip to main content
. 2018 Jun 18;10:1758835918777437. doi: 10.1177/1758835918777437

Figure 1.

Figure 1.

Optimal duration of endocrine therapy (ET).

The figure summarizes the evidence derived from clinical studies: the optimal duration of ET in different patient settings. Treatment options are those currently available for the first 5 years. High-risk patients are those who might require an extended treatment and their characteristics are defined in the text.

AI, aromatase inhibitor; LHRHa, luteinizing hormone-releasing hormone agonist; TAM, tamoxifen.